Details for Patent: 5,616,346
Summary for Patent: 5,616,346
| Title: | Non-aqueous colonic purgative formulations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of monobasic, dibasic and tribasic sodium phosphates administered in tablet or capsule form in concentrations of from 0.01 to 0.85 grams per kilogram body weight. Preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Craig A. Aronchick | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | ARONCHICK LIPSCHUTZ AND WRIGHT PARTNERSHIP , CDC III LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US08/669,834 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 5,616,346: Scope, Claims, Expiration, and Sodium Phosphate Purgative Patent LandscapeU.S. Patent No. 5,616,346 protected dry, orally administered sodium phosphate bowel-cleansing compositions in tablet or gelatin-capsule form and methods of using those dosage forms without first dissolving them in water. The patent issued April 1, 1997, and its enforceable term has expired. The patent therefore no longer blocks generic manufacture, sale, or use in the United States, although later patents, FDA requirements, product liability issues, and sodium-phosphate safety restrictions may still affect commercial entry. The claims are directed principally to the solid dosage-form concept associated with sodium phosphate bowel preparations such as Visicol and OsmoPrep, rather than to a new sodium phosphate molecule. What does U.S. Patent 5,616,346 protect?The patent has four substantive claim groups:
The patent does not broadly cover every sodium phosphate laxative. The strongest protection is directed to a dry dosage form that contains sodium phosphate salts and is administered orally without prior dispersion in water. The central commercial concept is a tablet or capsule that disperses after reaching the stomach and produces colonic purgation while reducing the volume of liquid the patient must drink compared with conventional aqueous bowel-preparation solutions. How should the independent claims be construed?Claim 1: solid sodium phosphate compositionClaim 1 requires a composition that:
The phrase "consisting essentially of" is important. It permits ingredients that do not materially alter the basic purgative operation of the composition but excludes additional active or functional components that materially change the invention. A liquid sodium phosphate preparation would fall outside the express tablet-or-capsule limitation of claim 1. A tablet containing a non-sodium-phosphate osmotic laxative as an additional active ingredient would face a substantial "consisting essentially of" issue. Claim 9: preparation and administration methodClaim 9 requires a sequence of steps:
This claim is narrower than a claim to sodium phosphate administration generally. It focuses on the dosage-form process and the absence of pre-administration dissolution. A product administered as a pre-mixed liquid would not satisfy the express dry-dosage-form limitations. A product supplied as a powder but routinely dissolved before administration would also create a noninfringement argument under the claim language. Claim 17: dosage and composition combinationClaim 17 requires:
This claim combines composition, dosage form, and dosing limitations. It is narrower than claim 1 and more vulnerable to noninfringement based on salt ratio, tablet composition, or administered dose. Claim 19: commercial-product profileClaim 19 is the most product-specific composition claim. It requires:
The percentages appear to describe the active salt blend used in commercial sodium phosphate tablets. Because the ranges collectively can total between 96% and 107%, the claim does not require a mathematically fixed 100% composition in every possible reading. In practice, however, a commercial formulation would normally be evaluated on a normalized weight basis. Which claim limitations create the main infringement risks?
The broadest practical risk under the issued claims concerns a tablet or gelatin capsule containing sodium phosphate as the operative purgative, administered without prior dissolution. Claims 2-4 and 17-19 create additional risk when the formulation approximates the monobasic/dibasic ratios used in commercial products. What formulations are protected by the patent?The patent claims the following formulation classes: Monobasic sodium phosphate formulationsClaim 2 identifies monobasic sodium phosphate at approximately 70%-73% by weight. This is a relatively narrow composition limitation and does not cover every monobasic sodium phosphate tablet. Dibasic sodium phosphate formulationsClaim 3 identifies dibasic sodium phosphate at approximately 26%-30% by weight. The claim does not require monobasic sodium phosphate unless that limitation is imported through another claim. Mixed monobasic and dibasic formulationsClaim 4 covers a mixture having approximately 70%-73% monobasic sodium phosphate and 26%-30% dibasic sodium phosphate. Claim 19 adds a 1%-4% range for inert additives and is more closely aligned with a finished commercial tablet. Tribasic-containing formulationsClaims 5, 15, and 16 include formulations containing tribasic sodium phosphate. Claims 6-8 address selected additives, including magnesium hydroxide, aluminum hydroxide, calcium carbonate, magnesium carbonate, lactose, microcrystalline cellulose, AC-DI-SOL, nonionic detergents, and mechanical adhesives. The additive claims are dependent claims. They do not independently protect the listed excipients in other drug products. They apply only when the base sodium phosphate composition and the other limitations of the referenced claim are present. When did U.S. Patent 5,616,346 lose exclusivity?The patent issued on April 1, 1997. Its 17-year patent term expired on April 1, 2014, subject to any patent-term adjustment or other term event recorded by the USPTO. Public patent records identify the patent as expired. The patent cannot currently provide enforceable United States exclusivity over the claimed sodium phosphate tablets or methods. (U.S. Patent No. 5,616,346, 1997; USPTO, n.d.) Because the patent is expired:
What is the Orange Book status of the patent?Patent 5,616,346 should be treated as an expired historical patent rather than a live Orange Book barrier. FDA Orange Book listing is product-specific and does not itself extend the patent term. A patent may be listed during a drug product's commercial life, but an expired listed patent does not create a current legal barrier to approval after expiration. (U.S. Food and Drug Administration, n.d.-a) The relevant FDA products include prescription sodium phosphate tablet bowel preparations such as Visicol and OsmoPrep. FDA labeling identifies sodium phosphate tablet products as requiring substantial liquid intake and includes warnings concerning renal injury, electrolyte abnormalities, and high-risk patient populations. (U.S. Food and Drug Administration, n.d.-b; U.S. Food and Drug Administration, n.d.-c) FDA approval does not establish freedom to operate. A later patent covering a formulation, coating, manufacturing process, dosing regimen, or approved use could remain relevant even after the 5,616,346 patent expired. What Paragraph IV challenges and litigation affected the patent?Paragraph IV litigation is relevant only while an Orange Book-listed patent is unexpired or otherwise legally enforceable. The expiration of 5,616,346 eliminates the patent as a current Paragraph IV obstacle. The commercial litigation risk for sodium phosphate tablets historically would have focused on:
A later generic product could still face litigation over separate patents. Patent 5,616,346 alone does not support a current infringement action. How does the patent compare with later sodium phosphate product protection?The patent has moderate historical strength but limited current commercial strength.
The patent does not protect a biologic and has no biosimilar pathway relevance. Sodium phosphate tablets are small-molecule drug products. Any follow-on competitor would generally evaluate an abbreviated new drug application, labeling requirements, bioequivalence, product quality, and clinical safety rather than a biosimilar application. What manufacturing and intellectual-property barriers remain?The expired patent does not eliminate operational barriers. A commercial entrant would still need to address:
The supplied claims contain no express protection for a specific compression process, coating process, packaging system, tablet tooling configuration, or impurity-control method. Those areas could be covered by later patents or trade secrets, but they are not protected by the quoted claims of Patent 5,616,346. What licensing deals and commercial relationships are relevant?The principal commercial history is associated with prescription sodium phosphate tablet products, including Visicol and OsmoPrep. Product commercialization, corporate acquisition, distribution, or marketing arrangements should not be treated as continuing patent licenses after the patent's expiration. No license is necessary to practice the expired claims. A party acquiring rights to a commercial brand, regulatory dossier, trademark, manufacturing technology, or later patent family could still require contractual rights, but those rights would be separate from Patent 5,616,346. What generic launch scenarios exist?Immediate tablet-based entryA manufacturer could develop a sodium phosphate tablet with a different salt ratio, alternative excipient system, or different dosing profile. Because Patent 5,616,346 is expired, the patent itself would not delay launch. Close formulation copyA product matching the 70%-73% monobasic and 26%-30% dibasic ranges would have faced historical claim risk during the patent term. Today, the principal obstacles would be FDA approval, safety, quality, and any later unexpired patents. Alternative dosage formA powder, liquid, effervescent product, or delayed-release dosage form could avoid the express tablet-or-gelatin-capsule limitations. The alternative would still require separate regulatory and technical validation. Lower-volume or modified regimenA lower-dose formulation could avoid the narrow method claims tied to specified gram-per-kilogram ranges. It would not automatically avoid broader composition claims during the historical patent term, but that issue is no longer operative because the patent has expired. What is the geographic scope of the patent?Patent 5,616,346 had United States territorial scope only. It did not directly control products sold in Canada, Europe, Japan, or other markets. Foreign equivalents, continuations, divisionals, and later improvement patents would require separate review. The expiration analysis above applies to the United States patent. It should not be extended automatically to foreign patent families or to later patents claiming the same commercial products. Key Takeaways
FAQsDoes Patent 5,616,346 cover liquid sodium phosphate bowel preparations?No. The quoted composition claims require a nonaqueous dosage form selected from tablets and gelatin capsules. A liquid product would not satisfy those express limitations. Does the patent cover any tablet containing sodium phosphate?No. The claims require a combination of limitations, including a purgative amount, a nonaqueous oral dosage form, and the claimed stomach-dispersal and purgation characteristics. The narrow claims also require specified salt ratios or dosing ranges. Can a generic manufacturer copy the monobasic and dibasic sodium phosphate ratios today?Patent 5,616,346 no longer prevents that conduct because the patent has expired. The manufacturer must still address other unexpired patents, FDA approval, labeling, quality, and safety requirements. Are the excipient claims independently enforceable?No. Claims 6-8 are dependent claims. They apply only when the underlying sodium phosphate composition and the limitations of the referenced claims are also satisfied. Does expiration of Patent 5,616,346 mean that Visicol or OsmoPrep can be marketed without FDA approval?No. Patent expiration removes one intellectual-property barrier. It does not eliminate the requirement for FDA approval, compliance with approved labeling, current good manufacturing practices, or applicable drug-safety controls. ReferencesU.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov U.S. Food and Drug Administration. (n.d.-b). OsmoPrep prescribing information. https://www.accessdata.fda.gov U.S. Food and Drug Administration. (n.d.-c). Visicol prescribing information. https://www.accessdata.fda.gov U.S. Food and Drug Administration. (2014). FDA drug safety communication: FDA recommends separating dosing of sodium phosphate products used for bowel cleansing. https://www.fda.gov U.S. Patent No. 5,616,346. (1997). Orally administrable sodium phosphate purgative compositions and methods. United States Patent and Trademark Office. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov More… ↓ |
Drugs Protected by US Patent 5,616,346
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,616,346
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 235894 | ⤷ Start Trial | |||
| Canada | 2241445 | ⤷ Start Trial | |||
| Germany | 69627170 | ⤷ Start Trial | |||
| Denmark | 0858326 | ⤷ Start Trial | |||
| European Patent Office | 0858326 | ⤷ Start Trial | |||
| Spain | 2196149 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
